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Background. Primary cutaneous lymphomas (PCL) comprise a heterogeneous group of neoplasms of mature lymphocytes 
with skin tropism. Although, by definition, these lymphomas are restricted to the skin at the time of diagnosis, during the 
course of the disease it may involve also  lymph nodes and visceral organs. A close cooperation between a dermatologist 
and oncologist is required to ensure proper treatment. We present in a real-life data on treatment of patients with PCL 
between dermatology and oncology department.
Material and methods. 104 patients were registered in a joined database of Oncology Department of Oncology Centre 
in Bydgoszcz and Dermatology Department of Medical University in Toruń between 2007 and 2017. Due to different 
clinical and prognostic features data from MF/SS (44 patients), non-MF/SS CTCLs and CBCLs were presented separately.
Results. Median overall survival for patients with MF/SS was 76.7 months. Median follow-up time was 5 years.
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Introduction
Primary cutaneous lymphomas (PCL) are rare extranodal non-
-Hodgkin lymphomas, 75% of them are derived from T lym-
phocytes (cutaneous T-cell lymphomas, CTCL) and 25% from 
B lymphocytes (cutaneous B-cell lymphomas, CBCL) [1–3].
CBCLs are divided into 3 subgroups: primary cutaneous 
follicle centre lymphoma (PCFCL), primary cutaneous marginal 
zone lymphoma (PCMZL), and primary cutaneous diffuse large 
B-cell lymphoma, leg type (PCDLBCL, LT) [1–3]. CTCLs comprise 
a group of distinct entities with significantly  varied clinical, 
histological and immunophenotypic features and prognoses.
The diagnosis and classification of PCL is based on histo-
logical assessment and immunohistochemical staining of an 
skin biopsy specimen. A prompt diagnosis is often difficult 
due to PCLs relative rarity and unspecific clinical presentations.
Mycosis fungoides (MF) and its leukemic phase, Sézary Syn-
drome (SS), is the most predominant subtype of CTCL ~53% [1–4]. 
MF can mimic different skin conditions, such as eczema, atopic 
dermatitis, psoriasis, and even other cutaneous lymphomas.
Histological findings are often unspecific and overlap with 
those of other inflammatory or non-neoplastic diseases so 
empirical treatment e.g. with topical steroids may hamper 
the diagnosis. MF has usually an indolent course and a good 
prognosis. Early-stage MF can be successfully managed by 
skin-directed therapy, advanced stages of MF and SS require 
systemic treatment modalities [4].
78
There is a relative scarcity of data regarding the treatment 
options of advanced stages CTCLs from non-dermatologi-
cal units in Poland [5–8]. The aim of this paper is to present 
real-life clinical data on therapeutic collaboration between 
dermatological and oncological department. The data have 
been prepared within the framework of the Polish Lymphoma 
Research Group.
Methods
104 patients were diagnosed with PCL between 2007 and 
2017 in Oncology Centre in Bydgoszcz and Dermatological 
Department of Medical University in Toruń.
The diagnosis of PCL was made when the clinical features 
were consistent with histological review and additional tests 
such as immunophenotyping. The PCL diagnosis was con-
firmed when lymphomatous infiltration was limited to the 
skin without any extracutaneous primary lesions found at the 
moment of diagnosis and subsequent 6 months of follow-up.
Initially, the patients with early stages of PCL were treated 
with skin-directed therapies such as PUVA or topical steroids. 
The first line of systemic therapy for advanced stages of PCL was 
either low-dose interferon alfa 2 beta (subcutaneous injection, 
3 million units, 3 times per week) or low-dose methotrexate (oral-
ly, 20 mg per week). Subsequent treatment options varied widely 
depending on the patient’s condition and drug availability.
Current paper focuses on the retrospective analysis of 
clinical data of unselected population of 44 patients diagno-
sed with MF/SS treated in years 2007–2013. 48 patients with 
MF/SS who were diagnosed after July 2014 were excluded 
from the analysis due to participation in the observational 
clinical trial (NCT 0232365). Due to distinct clinical features 
and prognosis, patients with non-MF/SS CTCLs and CBCLs are 
presented separately.
Statistical analysis comprised the calculation of overall 
survival, patients characteristics, previously applied treatment 
and coexisting comorbidities.
Results
The number of visits of the patients referred to the Dermatology 
Department in 2007–2017 with various dermatoses to confirm 
a suspicion of PCL are presented in table I. A confirmatory dia-
gnosis of PCL was made in 104 patients. The data from 2006–
2009 are not available due to technical reasons. The number of 
confirmed diagnosis of various types of PCL in 2007–2017 with 
ratio of non-MF PCLs to MF is presented in table II.
MF/SS was diagnosed in 92 patients (88.46% of PCLs); 44 
subsequent patients treated in 2007–2013 were included into 
the analysis. The median follow-up time was 5 years.
Table I. The number of visits in a dermatologic department caused by dermatoses or inflammatory dermatoses in relation to the number of visits of the 
patients with CTCL between 2010 and 2017
Year  Allergic Con-
tact dermati-
tis L23
Atopic skin der-
matitis
L20
Eczema
L30
Parapsoriasis
L41
Papulosqu-
amous disor-
ders L44
Contact der-
matitis
L24
All inflammatory 
dermatoses
 MF like 
2010 441 147 203 29 16 46 246
2011 489 158 139 61 6 125 198
2012 529 98 251 48 16 116 186
2013 575 40 288 69 14 164 212
2014 636 63 323 92 21 137 190
2015 796 70 477 115 36 98 219
2016 1263 187 804 137 20 115 184
2017 1489 193 997 160 30 109 140
The data from 2006 to 2009 are not available due to technical reasons. The growing number of civilizational skin diseases resulting from this visits and diagnostic needs draws 
special attention
Table II. The data from Oncologic Centre – the number of new patients 
with confirmed skin lymphoma. The proportion between more frequent 
type: MF (mycosis fungoides), SS (Sezary Syndrome) versus other types of 
skin lymphoma 
Year Number of new patients 
with confirmed skin 
lymphoma
Other type skin 
lymphoma/ 
/MF+SS
2007 6 1/5
2008 4 0/4
2009 5 0/5
2010 8 1/7
2011 14 2/12
2012 3 1/2
2013 15 2/13
2014 8 3/4
2015 16 2/14
2016 12 0/12
2017 13 0/12
All 104 12/92
These data comprise the whole 10 years period 2007–2017. Other skin lymphomas 
are represented both by B cell and T cell lymphoma: the details are shown in table 
III and IV. The number of diagnosed cutaneous lymphomas with respect to cases 
of dermatosis with a similar clinical picture (table I) was assessed to emphasise the 
scale of diagnostic needs in this area in everyday practice
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MF/SS was more prevalent in men (63%) and patients 
above 61 years (54%). Most patients (81.8%) were in stage III 
at the moment of the initiation of systemic treatment. The 
summary of clinical characteristics of the patients with MF/
SS is presented in table III. The frequency of comorbidities 
and other coexisting dermatoses is shown in table IV. Alcohol 
use disorder was retrospectively diagnosed in 22.72% of all 
MF/SS patients. The summary of data regarding the first line 
of systemic treatment is presented in table V.
Interferon (INF) as the first-line treatment was used in 
36 patients, methotrexate (MTX) was used in 8 patients. The 
median duration of treatment with interferon was 14 months 
and the median duration of treatment with methotrexate was 
10 months. 23 patients received 2 lines of systemic therapy, 
Table III. Clinical data of 44 MF/SS who started the treatment between 2007 to 2013, and have been follow up minimum 5 years 
Woman Men Age <60 Age >61 MF primary SS primary Stage IIB Stage III A/B1/not known B2
16 28 20 24 41 3 8 36 22/16/6 3
A – blood cytometry without any abnormalities, B1 – not clinically significant number of pathologic lymphocytes, B2 – significant number of pathologic lymphocyte
Table IV. The frequency of other skin diseases and comorbidities
Atopic dermatitis Skin allergy not 
specified
Parapsoriasis Other skin 
diseases
Cardio-vascular 
comorbidities
Diabetes ZZA Depression
44 27 17 40 24 23 10 17
ZZA – alcohol
Table V. The types of treatment and response 
Interferon I line/ 
/months of therapy 
Interferon RR Methotrexate I line/ 
/months of therapy-
medium value
Methotrexate RR SAE-Interferon SAE-Methotrexate
36 pts/3–120
Median: 14
CR–8, PR–28 8 pts/4–96
Median: 10
CR–2, PR–6 1 depression 1 infarctus
Death Alive patients Median OS Pts treated to 
progression without 
interval/median OS
Pts treated to PR and after 
progression/median OS
Patients post SCT/ 
/with CR
14 30 76.7 months 23/4–144 mts, median: 
74.3 mts
21/6–144 mts, median: 79.1 mts 4/4
pts – patients, SCT – stem cell transplantation
Table VI. CBCL and non MF/SS CTCL treatment details 
CBCL type/gender I line II line Maintenance Observation only/ 
/medium
number of visits 
per years 
Efficacy/ 
/I line
Relapse Time to  
II line
PCFCL/W COP No No No/7 CR No n.a
PCFCL/M No No No Yes/3 n.a n.a n.a
PCMZL/K AC due to breast cancer No No No/12 CR No n.a
PCDLBCL/W R-CHOP No No No/9 CR No n.a
FL/W R-CVP No No No/6 CR No n.a
FL/W R-CVP No Yes No/5 CR No n.a
DLBCL/W R-CHOP mini No No No/9 SD Yes n.a
LYP CD30+/W MTX n.a No No/12 CR No n.a
PCALCL ALK + CD 30+/M Surgery n.a No Yes/3 CR No n.a
PCALCL ALK–CD30+/W MTX/surgery ICE + SCT No n.a/12 CR Yes 15
PCALCL ALK+ CD 30+/M MTX MTX No n.a/6 CR No n.a
LYP CD 30–/W MTX/Interferon Bexarotene No No/12 SD Yes 56
CR – complete remission, PR – partial remission, SD – stabilisation, PD – progression, W – woman, M – man, PCFCL – primary cutaneous follicle centre lymphoma, PCMZL – 
primary cutaneous marginal zone lymphoma, PCDLBCL LT – primary cutaneous diffuse large B-cell lymphoma (leg type), PCALCL – primary cutaneous anaplastic large cel 
lymphoma, LYP – lymphomatoid papulosis, n.a – not applicable 
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15 patients – 3 lines and 15 patients – more than 3 lines (9 pts 
– 4 lines, 5 pts – 5 lines, 1 pt – 6 lines). The chemotherapy 
regimens used for relapsed or refractory disease beyond the 
second-line therapy were as follows: gemcytabine (10 pts), 
liposomal doxorubicin (11 pts), cytarabine (4 pts), pralatrexate 
(1 pt), bexarotene (8 pts). 
Stem cell transplant (SCT) was performed in 4 patients after 
achieving remission after the  use of romidepsin as an induction 
therapy (3 pts – allogeneic SCT, 1 pt – allogeneic SCT). 2 patients 
participated in Millennium clinical trial and received alisertib 
and pralatrexate. Overall survival data is presented in table VI.
There were 7 patients with CBCL. Patients with CBCL re-
ceived rituximab-containing chemotherapy regimens. 1 pa-
tient with synchronic and breast cancer was treated with AC 
chemotherapy with subsequent breast-conserving surgery 
followed by radiotherapy.
5 patients have had a long-term remission. 2 patients with 
CBCLS died: 90 year old man due to a cardiovascular disease 
and 78-year old woman due to the disease progression; pa-
tients were diagnosed with lymphomatoid papulosis (CD30+ 
– 1 pts, CD30– – 1 pts) and 3 patients were diagnosed with 
primary cutaneous anaplastic large cell lymphoma CD30+ 
(ALK– – 1 pt, ALK+ – 2 pts).
A patient with PCALCL ALK+ received a complete remis-
sion after polychemotherapy and treatment was consolidated 
by allogeneic HCT. A patient with LyP CD30+, resistant to initial 
MTX and INF treatment, received bexarotene treatment with 
long-lasting partial remission despite the need for a significant 
dose reduction of bexarotene. Tables VI and VII presents clinical 
course and survival data CBCLS and non MF/SS lymphoma.
Discussion
CTCLs comprise a group of heterogeneous lymphomas with 
a varied clinical behaviour. Most CBCLs are indolent lympho-
mas that infrequently infiltrate extracutaneous sites, have 
a good prognosis and may be effectively managed with lo-
cally targeted therapies. The advanced stages of CBCLs require 
immunochemotherapy as other nodal non-Hodgkin lympho-
mas. The data presented in this paper regarding CBCLs and its 
clinical features are consistent with other reports [1, 2]. CTCL is 
the most dominant type of PCL. Most dominant subtypes of 
CTCL were MF/SS (44 pts), CD30+-lymphomas; other subtypes 
like PCALCL and LyP were rare (5 pts). Low-dose methotrexate 
is a frequent first line therapy for multifocal PCALCL with good 
clinical results and the rate of complete remission near 40% [9].
Two patients were MTX-resistant and required subsequent 
therapy. 1 patient was successfully managed by the surgical 
removal of a skin lesion.
Although MF is the most common type of PCL, the reports 
regarding treatment options is relatively sparse. A broad spec-
Table VII. Clinical data and overall survival in CBCL and patients with non MF/SS
Type 
PCL
Sex Age First 
visit
Other skin 
diseases
Comorbidities Stage Alive 
yes or no/OS 
Date of death
PCFCL W 59 V 2007 Any (–) T4N0M0
Symptoms B+
Yes/141 months n.a
PCFCL M 90 IV 2014 Any Dementia T4N1M0 No/14 months  June 2015
PCMZL W 64 VII 2013 Any Breast cancer T3N0M0 Yes/67 months n.a
PCDLBCL leg 
type
W 49 IX 2014 Any Diabetes I X A Yes/54 months n.a
PCFCL W 59 X 2015 Any (–) T4N0M0 Yes/39 months n.a
PCFCL W 70 VII 2014 Any Hypertension T4N0M0 Yes/52 months n.a
PCDLBCL leg 
type
W 78 III 2015 Any Diabetes, 
hypretension
T4N1M0 No/8 months October 2015
LYP CD30+ W 64 III 2010 Hypertension Atopic 
dermatitis
T3N0M0 Yes/106 months n.a
PCALCL 
ALK+
 CD 30+
M 44 V 2011 Any (–) T1N0M0 Yes/91 months n.a
PCALCL 
ALK–
CD 30+
W 47 XI 2011 Any (–) T3N0M0 Yes/85 months n.a
PCALCL 
AKL+CD30+
M 39 II 2012 Any (–) T3N0M0 Yes/82 months n.a
LYP CD30– W 72 I 2013 Coronary 
disease
Skin allergy not 
specified
T4N1M0 Yes/72 months n.a
W – woman, M – man, PCFCL – primary cutaneous follicle centre lymphoma, PCMZL – primary cutaneous marginal zone lymphoma, PCDLBCL LT – primary cutaneous diffuse 
large B-cell lymphoma (leg type), OS – overall survival, PCALCL – primary cutaneous anaplastic large cell lymphoma, LYP – lymphomatoid papulosis, n.a – not applicable 
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trum of clinical features of MF may be initially missed and thus 
adequate therapeutic measures delayed.
Another problem regarding the treatment of MF is the limited 
access to novel drugs due to reimbursement decisions. Currently 
in Poland there is no access to treatment options like romidepsin 
and other HDAC inhibitors, denileukin diftitox, pegylated liposo-
mal doxorubicin or extracorporeal photopheresis. [13–16]. For an 
early stage MF confined to the skin, the therapeutic concept is to 
control symptoms by use of skin-directed therapies e.g. topical 
agents such as corticosteroids, mechlorethamine, carmustine, 
retinoids, phototherapy, superficial radiotherapy, and total skin 
electron beam therapy. Due to chronic and recurrent nature of MF, 
in advanced stages, repeated systemic treatment are necessary 
for disease control [19, 20]. Possible systemic treatment options 
are: bexarotene, interferon-α, histone deacetylase inhibitors, de-
nileukin diftitox, chemotherapy [13, 19, 21].
Single-agent chemotherapies with a high overall response 
rate (ORR) are as follows [13–16, 21]: pegylated liposomal do-
xorubicin (ORR = 88% in stage IA–IV 88%), gemcitabine (ORR 
= 70% in stage IIB–III), fludarabine (ORR = 55% in stage IIA–IV) 
[17]. Fludarabine can be substituted by cytarabine because 
of its favourable safety profile – it was used in 4 patients as 
salvage therapy. Allogeneic HCT is currently the curative tre-
atment option advanced and resistant MF/SS for young and 
otherwise healthy patients [19, 21]. The median overall survival 
for advanced stage MF reported in literature (IIB–IVA) is 60 
months [17, 21, 23]. In this study median OS was 75 months.
The aim of this analysis was to confront the treatment options 
recommended in professional guidelines with every-day practice. 
In the author’s opinion, a limited access to the novel drugs and a 
small number of clinical trials in Poland make many of proposed 
treatment modalities a not viable option for the Polish population 
[17, 24]. Because of the rarity and a varied natural course of the 
MF, ranging from indolent to highly aggressive, the close coope-
ration between a dermatologist and an oncologist in important. 
In Poland there are formal limitations regarding which  kind of 
treatment can be applied by a specific specialist [25]. Recently, 
radiotherapy has been more frequently used than in the past, 
but extracorporeal photopheresis is still not available because of 
reimbursement issues (the exception is GVHD after allo-SCT) [20].
The debate concerning the best way of treatment of  these 
rare lymphoprolfierative disorders is necessary. Researchers 
hope that increased understanding of the pathogenesis of 
cutaneous lymphomas with identification of important mo-
lecular markers will lead to the development of new targeted 
therapies and a better effectiveness of the treatment [26].
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